ASO Visual Abstract: Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients

被引：0
作者：
Chen, Zongshun [1 ,2 ]
Zhang, Jing [3 ]
Chen, Wei [1 ,2 ]
Chen, Xueyi [2 ,4 ]
Lu, Da-Lin [3 ]
Li, Junjie [2 ]
机构：
[1] Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Chengdu, Peoples R China
[2] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Dept Breast Surg, Chengdu, Peoples R China
[3] Jinan Univ, Sch Med, Dept Epidemiol, Jinan, Guangdong, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Dept Breast Surg,Sch Med,Sichuan Canc Ctr, Chengdu, Peoples R China
来源：
ANNALS OF SURGICAL ONCOLOGY | 2025年
关键词：
D O I：
10.1245/s10434-025-17243-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4061 / 4062
页数：2
相关论文
共 50 条
  • [1] Serum Enzymes and Pathologic Complete Response to the Addition of Targeted Therapy in Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer Patients
    Chen, Zongshun
    Zhang, Jing
    Chen, Wei
    Chen, Xueyi
    Lu, Da-Lin
    Li, Junjie
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 4008 - 4016
  • [2] ASO Author Reflections: Serum Enzymes as Predictive Biomarkers for Pathologic Complete Response in HER2-Positive Breast Cancer
    Chen, Zongshun
    Zhang, Jing
    Chen, Wei
    Chen, Xueyi
    Lu, Da-Lin
    Li, Junjie
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (06) : 4055 - 4056
  • [3] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    Mette S. van Ramshorst
    Claudette E. Loo
    Emilie J. Groen
    Gonneke H. Winter-Warnars
    Jelle Wesseling
    Frederieke van Duijnhoven
    Marie-Jeanne T. Vrancken Peeters
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2017, 164 : 99 - 106
  • [4] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    van Ramshorst, Mette S.
    Loo, Claudette E.
    Groen, Emilie J.
    Winter-Warnars, Gonneke H.
    Wesseling, Jelle
    van Duijnhoven, Frederieke
    Peeters, Marie-Jeanne T. Vrancken
    Sonke, Gabe S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 99 - 106
  • [5] ASO Author Reflections: Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy
    Tina J. Hieken
    Tanya L. Hoskin
    Annals of Surgical Oncology, 2022, 29 : 597 - 598
  • [6] ASO Author Reflections: Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy
    Hieken, Tina J.
    Hoskin, Tanya L.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 3) : 597 - 598
  • [7] Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting
    Sheikh, Fareeha
    Nazir, Adil
    Yasmeen, Samia
    Badar, Farhana
    Ahmad, Usman
    Siddiqui, Neelam
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (02): : 159 - 163
  • [8] Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy
    Rosario, Mariela Huerta
    Sahoo, Sunati
    CANCER RESEARCH, 2020, 80 (04)
  • [9] Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy
    Wang, Xinguang
    He, Yingjian
    Fan, Zhaoqing
    Wang, Tianfeng
    Xie, Yuntao
    Li, Jinfeng
    Ouyang, Tao
    BREAST CARE, 2019, 14 (06) : 388 - 393
  • [10] Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Fujii, Takeo
    Kogawa, Takahiro
    Wu, Jimin
    Sahin, Aysegul A.
    Liu, Dian D.
    Chavez-MacGregor, Mariana
    Giordano, Sharon H.
    Raghavendra, Akshara
    Murthy, Rushmy K.
    Tripathy, Debu
    Shen, Yu
    Yamal, Jose-Miguel
    Ueno, Naoto T.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 509 - 514
12345